Kir2.1 Mutations Differentially Increase the Risk of Flecainide Proarrhythmia in Andersen Tawil Syndrome

Background: Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts.

Methods And Results: Of 53 ATS1 patients reviewed from the literature, 54% responded partially to flecainide, with ventricular arrhythmia (VA) reduction in only 23%. Of the latter patients, VA persisted in 20-50%. Flecainide was ineffective in 23%, and surprisingly, 13.5% suffered a non-fatal cardiac arrest. In five cardiac-specific ATS1 mouse models (Kir2.1, Kir2.1, Kir2.1 and Kir2.1 and Kir2.1), flecainide or propafenone (40 mg/Kg i.p.) differentially prolonged the P wave, and the PR, QRS and QTc intervals compared to Kir2.1; Kir2.1 had milder effects. Flecainide increased VA inducibility in all mutant mice except Kir2.1, which exhibited significant VA reduction. At baseline, Kir2.1 cardiomyocytes had the lowest inward rectifier K+ channel (I) reduction, followed by Kir2.1, Kir2.1 and Kir2.1. Kir2.1 cardiomyocytes had a significant decrease in sodium inward current (I). Flecainide (10 μM) slightly increased I density in Kir2.1 and Kir2.1, while it decreased both I and I in Kir2.1 and Kir2.1, despite normal trafficking of mutant channels. Optical mapping in ATS1 patient-specific iPSC-CM monolayers expressing Kir2.1, Kir2.1 and Kir2.1 showed an increase in rotor incidence at baseline and under flecainide, confirming the drugś proarrhythmic effect. Lastly, in-silico molecular docking predicts that the Kir2.1-Cys pharmacophore-binding site is altered in Kir2.1 heterotetramers, reducing flecainide accessibility and leading to channel closure and arrhythmias.

Conclusions: Class-Ic AADs are only partially effective and might be proarrhythmic in some ATS1 patients. Kir2.1 mutations impacting the resting membrane potential and cellular excitability create a substrate for life-threatening arrhythmias, raising significant concern about using these drugs in some ATS1 patients.

References

Tristani-Firouzi M, Etheridge S . Kir 2.1 channelopathies: the Andersen-Tawil syndrome. Pflugers Arch. 2010; 460(2):289-94. DOI: 10.1007/s00424-010-0820-6. View

Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding W . Phenotype variability in patients carrying KCNJ2 mutations. Circ Cardiovasc Genet. 2012; 5(3):344-53. DOI: 10.1161/CIRCGENETICS.111.962316. View

Platia E, Estes M, Heine D, Griffith L, Garan H, Ruskin J . Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol. 1985; 55(8):956-62. DOI: 10.1016/0002-9149(85)90726-x. View

SINGER D, LAZZARA R, Hoffman B . Interrelationship between automaticity and conduction in Purkinje fibers. Circ Res. 1967; 21(4):537-58. DOI: 10.1161/01.res.21.4.537. View

Xiao X, Li J, Samulski R . Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998; 72(3):2224-32. PMC: 109519. DOI: 10.1128/JVI.72.3.2224-2232.1998. View

Abriel H, Rougier J, Jalife J . Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death. Circ Res. 2015; 116(12):1971-88. PMC: 4471480. DOI: 10.1161/CIRCRESAHA.116.305017. View

Winkle R, Mason J, GRIFFIN J, Ross D . Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J. 1981; 102(5):857-64. DOI: 10.1016/0002-8703(81)90036-3. View

Hosaka Y, Hanawa H, Washizuka T, Chinushi M, Yamashita F, Yoshida T . Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome. J Mol Cell Cardiol. 2003; 35(4):409-15. DOI: 10.1016/s0022-2828(03)00046-4. View

Erdogan O, Aksoy A, Turgut N, Durusoy E, Samsa M, Altun A . Oral verapamil effectively suppressed complex ventricular arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome. J Electrocardiol. 2008; 41(4):325-8. DOI: 10.1016/j.jelectrocard.2008.02.023. View

10.

Barajas-Martinez H, Hu D, Ontiveros G, Caceres G, Desai M, Burashnikov E . Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. Circ Cardiovasc Genet. 2010; 4(1):51-7. PMC: 3041844. DOI: 10.1161/CIRCGENETICS.110.957696. View

11.

Fernandez M, Del Rosario Marin M, Fernandez-Armenta J, Mora-Lopez F, Fernandez Rivero R, Berruezo A . Response to flecainide test in Andersen-Tawil syndrome with incessant ventricular tachycardia. Pacing Clin Electrophysiol. 2017; 41(4):429-432. DOI: 10.1111/pace.13204. View

12.

Janson C, Poelzing S, Shah M . Combined inhibition of Na⁺ and Ca²⁺ channels: a novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome. Heart Rhythm. 2013; 11(2):318-20. DOI: 10.1016/j.hrthm.2013.11.003. View

13.

Junker J, Haverkamp W, Schulze-Bahr E, Eckardt L, Paulus W, Kiefer R . Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. 2002; 59(3):466. DOI: 10.1212/wnl.59.3.466. View

14.

O Brien S, Holmes A, Johnson D, Kabir S, O Shea C, O Reilly M . Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels. J Mol Cell Cardiol. 2022; 166:23-35. PMC: 7616974. DOI: 10.1016/j.yjmcc.2022.01.009. View

15.

Wang D, Kiyosue T, Sato T, Arita M . Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1996; 28(5):893-903. DOI: 10.1006/jmcc.1996.0084. View

16.

Bagal S, Marron B, Owen R, Storer R, Swain N . Voltage gated sodium channels as drug discovery targets. Channels (Austin). 2015; 9(6):360-6. PMC: 4850042. DOI: 10.1080/19336950.2015.1079674. View

17.

Weir R, Petrie C, Murday V, Findlay I . Andersen-Tawil syndrome. Int J Cardiol. 2009; 148(1):e13-5. DOI: 10.1016/j.ijcard.2009.01.057. View

18.

Radicke S, Vaquero M, Caballero R, Gomez R, Nunez L, Tamargo J . Effects of MiRP1 and DPP6 beta-subunits on the blockade induced by flecainide of Kv4.3/KChIP2 channels. Br J Pharmacol. 2008; 154(4):774-86. PMC: 2439850. DOI: 10.1038/bjp.2008.134. View

19.

Melgari D, Zhang Y, El Harchi A, Dempsey C, Hancox J . Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. J Mol Cell Cardiol. 2015; 86:42-53. PMC: 4564290. DOI: 10.1016/j.yjmcc.2015.06.021. View

20.

Mazzanti A, Guz D, Trancuccio A, Pagan E, Kukavica D, Chargeishvili T . Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. J Am Coll Cardiol. 2020; 75(15):1772-1784. DOI: 10.1016/j.jacc.2020.02.033. View